Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market with Covid-19 Pandemic Analysis, Growth Rate, New Trend Analysis Forecast by 2028 | Pfizer, Inc., Valeant Pharmaceuticals Inc., Novartis AG, Bayer AG & so on…
The approximately US$ 25 Bn market for benign prostatic hyperplasia prostate treatment is likely to expand at 4.6% CAGR during 2018-2028, according to a recent research report of Future Market Insights (FMI). The report has envisaged steady growth prospects for the revenue of global benign prostatic hyperplasia prostate treatment market through 2028.
The World Population Prospects’ data (2017) projected that the number of individuals aged 60 years and above will double by 2050, and triple by 2100. With such a high pace estimated for the growth of population aged 60 years and above, it is more likely that the prevalence of aging related health conditions will also increase at a considerable pace in the years to come. A high prevalence rate of benign prostatic hyperplasia (BPH) in men, the demand for improved and more effective treatment options continues to increase at a high rate.
Alpha-blockers & Drugs for Lower UTIs Remain Pivotal in Benign Prostatic Hyperplasia Prostate Treatment
The drug treatment has been vital in treating benign prostatic hyperplasia conditions and lower UTIs, which has been attributed to widespread availability of drug-based benign prostatic hyperplasia prostate treatment. This factor, in particular, will play an instrumental role in driving the growth of the benign prostatic hyperplasia prostate treatment market during the forecast period. Drugs will remain the first choice of treatment for benign prostatic hyperplasia.
Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1664
Benign prostatic hyperplasia increases the risk of other disorders as well. The most common disorder caused due to benign prostatic hyperplasia is lower UTI (urinary tract infection) for which, Alpha-blockers constitute the first line of treatment. However, other drugs are also available in the market, which offer relief from the benign prostatic hyperplasia symptoms. Other drugs include alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs.
Demand for Benign Prostatic Hyperplasia Prostate Treatment Higher in Developed Regions, Patient Pool Expanding Steadily in Developing Markets
Owing to significantly growing prevalence of benign prostatic hyperplasia in North American men, benign prostatic hyperplasia prostate treatment market is expected to witness strong growth within the region, followed by Europe.
Extensive availability of benign prostatic hyperplasia prostate treatments, increasing clinical trials, improving R&D scenario, higher healthcare spending, and favorable government initiatives will continue to assist the growth of the benign prostatic hyperplasia prostate treatment market in developed regions.
On the other side, Asia Pacific’s benign prostatic hyperplasia prostate treatment market is foreseen to witness significant growth, owing to steadily expanding patient pool due in the region.
Preview Analysis Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Segmented By Treatment Type (drugs(alpha-blockers, alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs), devices (prostatic stents, suture base implant systems, and transurethral RF thermal therapy)); By Distribution Channel (Institutional sales (hospitals, ambulatory surgical centers, and specialty clinics), retail sales (retail pharmacies and drug stores), and online pharmacies) : https://www.futuremarketinsights.com/reports/benign-prostatic-hyperplasia-bph-and-prostate-treatment-market
UroLift System to Revolutionize the Competitive Landscape of Benign Prostatic Hyperplasia Prostate Treatment Market
Teleflex Incorporated’s NeoTract recently launched UroLift® System as a highly effective, least invasive option for benign prostatic hyperplasia prostate treatment. The UroLift® System is permanently implanted via a transurethral outpatient procedure and predominantly relieves prostate obstruction, which is one of the primary symptoms of benign prostatic hyperplasia. The company has also declared insurance coverage for UroLift® System. While the coverage is being provided by Humana, it is most likely to improve awareness about increasing availability and broadening access of minimally invasive treatment methods in urological conditions such as benign prostatic hyperplasia. This in turn will encourage adoption of UroLift® System among patients seeking effective benign prostatic hyperplasia prostate treatment.
Get full Report Now@ https://www.futuremarketinsights.com/checkout/1664
A majority of patients with enlarged prostate continue to perceive medication and surgery as the only available treatment alternatives. However, an increasing number of physician recommendations is advocating the use of The UroLift® System as it eliminates side effects associated with other conventional options of benign prostatic hyperplasia prostate treatment.
Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-1664
More from FMI’s Healthcare, Pharmaceuticals and Medical devices Market Intelligence:
- Retinal Biologics Market Opportunity Assessment – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 to 2028
- Contouring Implants Market Analysis – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2028
- Aldosteronism Treatment Market Analysis – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2028
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: firstname.lastname@example.org
For Media Enquiries: email@example.com